Publications
107 results found
Zhang H, Koo CY, Stebbing J, et al., 2013, The dual function of KSR1: a pseudokinase and beyond, BIOCHEMICAL SOCIETY TRANSACTIONS, Vol: 41, Pages: 1078-1082, ISSN: 0300-5127
- Author Web Link
- Cite
- Citations: 33
Stebbing J, Filipovic A, Lit LC, et al., 2013, LMTK3 is implicated in endocrine resistance via multiple signaling pathways, ONCOGENE, Vol: 32, Pages: 3371-3380, ISSN: 0950-9232
- Author Web Link
- Cite
- Citations: 35
Filipovic A, Stebbing J, Giamas G, 2013, Quackery Cancer stem cells-therapeutic targeting or therapy?, LANCET ONCOLOGY, Vol: 14, Pages: 579-580, ISSN: 1470-2045
- Author Web Link
- Cite
- Citations: 2
Xu Y, Filipovic A, Zhang H, et al., 2013, The role of LMTK3 in breast cancer cell growth and invasion, 104th Annual Meeting of the American-Association-for-Cancer-Research (AACR), Publisher: AMER ASSOC CANCER RESEARCH, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 1
Lit LC, Scott S, Zhang H, et al., 2013, LATS2 Is a Modulator of Estrogen Receptor Alpha, ANTICANCER RESEARCH, Vol: 33, Pages: 53-63, ISSN: 0250-7005
- Author Web Link
- Cite
- Citations: 15
Zhang H, Lombardo Y, Filipovic A, et al., 2012, KSR1 is involved in functional interaction between p53 and BRCA1 and is an independent predictor of overall survival in breast cancer, CANCER RESEARCH, Vol: 72, ISSN: 0008-5472
Giamas G, Xu Y, Filipovic A, et al., 2012, The involvement of LMTK3 in endocrine resistance is mediated via multiple signaling pathways, CANCER RESEARCH, Vol: 72, ISSN: 0008-5472
Lombardo Y, Filipovic A, Molyneux G, et al., 2012, Nicastrin regulates breast cancer stem cell properties and tumor growth in vitro and in vivo, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, Vol: 109, Pages: 16558-16563, ISSN: 0027-8424
- Author Web Link
- Cite
- Citations: 60
Zhang H, Photiou A, Grothey A, et al., 2012, The role of pseudokinases in cancer, CELLULAR SIGNALLING, Vol: 24, Pages: 1173-1184, ISSN: 0898-6568
- Author Web Link
- Cite
- Citations: 27
Schirripa M, Loupakis F, Cremolini C, et al., 2012, KSR1 GENE POLYMORPHISM IN MCRC PATIENTS TREATED WITH FIRST-LINE FOLFIRI AND BEVACIZUMAB, 14th World Congress on Gastrointestinal Cancer of the European-Society-for-Medical-Oncology (ESMO), Publisher: OXFORD UNIV PRESS, Pages: 24-24, ISSN: 0923-7534
Zhang W, Benhaim L, Yang D, et al., 2012, Genetic variants of kinases suppressors of ras (KSR1) to predict survival in patients with ER-alpha positive metastatic breast cancer., 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
Schirripa M, Loupakis F, Cremolini C, et al., 2012, <i>KSR1</i> gene polymorphism in mCRC patients treated with first-line FOLFIRI and bevacizumab, 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
Barzi A, Wakatsuki T, Zhang W, et al., 2012, Prognostic value of lemur tyrosine kinase-3 (LMTK3) polymorphism in Japanese (J) patients (PTS) with localized gastric adenocarcinoma (GAC)., 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
Zhang HXJ, Paez D, Giamas G, et al., 2012, Genetic variants in human epidermal growth factor receptor (HER) family gene predict tumor recurrence in breast cancer, CANCER RESEARCH, Vol: 72, ISSN: 0008-5472
- Author Web Link
- Cite
- Citations: 1
Giamas G, Zhang H, Zhang W, et al., 2012, Identification of novel kinases involved in Estrogen receptor-α (ERα) signalling and the development of endocrine resistance in breast cancer, CANCER RESEARCH, Vol: 72, ISSN: 0008-5472
Jiao LR, Frampton AE, Jacob J, et al., 2012, MicroRNAs Targeting Oncogenes Are Down-Regulated in Pancreatic Malignant Transformation from Benign Tumors, PLOS ONE, Vol: 7, ISSN: 1932-6203
- Author Web Link
- Open Access Link
- Cite
- Citations: 109
Loupakis F, Zhang W, Gerger A, et al., 2012, LMTK3 polymorphism in patients with metastatic colon cancer., Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
Zhang W, Gerger A, Labonte MJ, et al., 2012, Association of gender-related tumor recurrence with a polymorphic variant of LMTK3 in stage II and III colon cancer., Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
Wakatsuki T, Bohanes PO, Zhang W, et al., 2012, Use of genetic variants of LMTK3 to predict tumor recurrence in female localized gastric adenocarcinoma., Publisher: AMER SOC CLINICAL ONCOLOGY, ISSN: 0732-183X
Filipovic A, Giamas G, Stebbing J, 2011, The potential role of cyclooxygenase-2 (COX-2) during early breast cancer therapy, ANNALS OF ONCOLOGY, Vol: 22, Pages: 1700-1702, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 2
Stebbing J, Filipovic A, Ellis IO, et al., 2011, LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome., Breast Cancer Res Treat, ISSN: 1573-7217
Interactions between kinases and the estrogen receptor α (ERα) are thought to be a critical signaling pathway in the majority of human breast cancers. We have recently identified a previously uncharacterized molecule, lemur tyrosine kinase-3 (LMTK3) as a prognostic and predictive oncogenic ERα regulator with a central role in endocrine resistance. Unusually this protein has undergone Darwinian positive selection between Chimpanzees and humans suggesting it may contribute to human susceptibility to ERα-positive tumors. Using over 600 European primary breast cancer cases, we wished to establish tumor characteristics associated with both cytoplasmic and nuclear LMTK3 expression, and then externally validate our observed European clinical outcomes with samples from Asian individuals receiving chemotherapy. Both nuclear and cytoplasmic expression correlated with tumor grade (P < 0.001) and in the Asian cohort, independent blinded analyses demonstrated that high basal LMTK3 expression was associated with advanced stage of primary breast cancers as well as decreased overall (P = 0.03) and disease-free survival (P = 0.006). In summary, higher LMTK3 expression is associated with more aggressive cancers. These data support our previous findings and suggest LMTK3 expression may be a reliable new biomarker in breast cancer.
Stebbing J, Filipovic A, Giamas G, 2011, LMTK3 and evolution, Oncotarget
Stebbing J, Filipović A, Giamas G, 2011, Lemur tyrosine kinase-3 (LMTK3) in cancer and evolution., Oncotarget, Vol: 2, Pages: 428-429
Stebbing J, Filipovic A, Giamas G, 2011, Lemur tyrosine kinase-3 (LMTK3) in cancer and evolution, ONCOTARGET, Vol: 2, Pages: 428-429
- Author Web Link
- Open Access Link
- Cite
- Citations: 10
Giamas G, Filipovic A, Messier W, et al., 2011, Kinome Screening for Regulators of Estrogen Receptor Identifies a Novel Kinase as a New Therapeutic Target in Breast Cancer.
Winder T, Giamas G, Zhang W, et al., 2011, Use of insulin-like growth factor (IGF) pathway polymorphism IGF1R_rs2016347 to predict tumor recurrence in estrogen receptor-positive breast cancer patients, JOURNAL OF CLINICAL ONCOLOGY, Vol: 29, ISSN: 0732-183X
- Author Web Link
- Cite
- Citations: 1
Giamas G, Filipovic A, Jacob J, et al., 2010, Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer, Nature Medicine, Vol: 17(6), Pages: 715-719
Filipovic A, Giamas G, Coombes RC, et al., 2010, Gamma secretase and Notch as therapeutic targets in cancer, Advances in Breast Cancer, Vol: 7
Man YL, Filipovic A, Stebbing J, et al., 2010, New and established targets for the treatment of breast cancer, Advances in Breast Cancer, Vol: 7
Giamas G, Man YL, Hirner H, et al., 2010, Kinases as targets in the treatment of solid tumors, CELLULAR SIGNALLING, Vol: 22, Pages: 984-1002, ISSN: 0898-6568
- Author Web Link
- Cite
- Citations: 67
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.